Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy through its brain-responsive RNS System. The NeuroPace news feed on Stock Titan highlights company announcements that relate to financial performance, clinical evidence, regulatory milestones, reimbursement developments, and technology progress in neuromodulation and AI-enabled epilepsy care.
Investors and clinicians following NPCE can find updates on quarterly and annual financial results, revenue trends driven by RNS System sales, and guidance for future periods. NeuroPace frequently reports on gross margin performance, operating expenses, and strategic decisions such as focusing organizational efforts on its differentiated RNS System and treating certain distribution activities as discontinued operations for reporting purposes.
The news flow also includes clinical and regulatory developments, such as preliminary data from the NAUTILUS trial in antiseizure-medication resistant idiopathic generalized epilepsy (IGE), which has shown substantial median reductions in generalized tonic-clonic seizures and a favorable safety profile. NeuroPace provides updates on its Premarket Approval Supplement submissions to the U.S. Food and Drug Administration (FDA) for expanded RNS System indications, Breakthrough Device Designation for IGE, and progress in pediatric and AI software programs.
Another important category of news involves reimbursement and policy. NeuroPace has announced favorable Medicare Physician Fee Schedule and Outpatient Prospective Payment System decisions that increase reimbursement for RNS System implantation and replacement procedures and maintain stable inpatient classifications, developments the company describes as supportive of neurosurgeon adoption and patient access.
In addition, the NPCE news stream features participation in major medical and investor conferences, including the American Epilepsy Society Annual Meeting and large healthcare investment conferences, where NeuroPace presents Post-Approval Study data, NAUTILUS results, and demonstrations of NeuroPace AI and SeizureID tools. Users who want to monitor how clinical evidence, reimbursement, and AI-enabled tools evolve around the RNS System can review and revisit this news page for the latest company-issued information and event updates.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, announced that data from their RNS System Post-approval Study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting. The presentation, titled 'Multicenter Post-approval Study of the RNS System in Focal Epilepsy,' will be delivered by Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of UCLA Seizure Disorders Center. The session is scheduled for Monday, April 7th, at 5:06 PM PT during the Epilepsy Clinical Outcomes and Prognostication session at the conference being held in San Diego from April 5th to 9th.
NeuroPace (NPCE) has announced its 2025 financial guidance and three-year strategic objectives. The company projects 2025 revenue between $92-96 million, representing 15.5-20.5% growth from 2024's expected range of $79.4-79.9 million. The gross margin target is set at 73-75%, with total operating expenses projected at $92-95 million, including $11 million in stock-based compensation.
The company's three-year strategic plan aims to establish NeuroPace as the leader in drug-resistant epilepsy therapy, targeting a 20%+ revenue CAGR. Key objectives include expanding indications to Idiopathic Generalized and Pediatric drug-resistant epilepsy patients, advancing AI tools and remote programming capabilities, enhancing patient awareness through direct-to-consumer campaigns, and achieving cash flow breakeven.
NeuroPace (NPCE) announced preliminary unaudited Q4 2024 revenue between $21.0-21.5 million, representing 17-19% growth versus Q4 2023. Full-year 2024 revenue is expected between $79.4-79.9 million, showing 21-22% growth compared to 2023 and exceeding initial guidance of $73-77 million.
The company reported cash and short-term investments of $52.8 million as of December 31, 2024, with 30,145,039 total shares outstanding. The NAUTILUS pivotal trial, evaluating RNS System for drug-resistant idiopathic generalized epilepsy, is on track to complete one-year follow-up in March 2025.
Scott Huennekens was appointed to NeuroPace's Board of Directors effective January 6th, 2025. The company will present at the J.P. Morgan Healthcare Conference on January 15th and host an Investor Day on January 28th in New York City.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA.
In addition to the presentation, the management team will engage in investor meetings throughout the conference. Interested parties can access the presentation through a live webcast, and a replay will remain available for two weeks following the event on the Events section of NeuroPace's Investor website.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced an upcoming Investor Day scheduled for January 28, 2025, in New York City. The event will run from 9:00 a.m. to 12:00 p.m. ET.
The presentation will showcase the company's RNS technology and future strategic plans. Management will discuss recent results and outline market, product, and clinical development strategies for the RNS System. The event will feature presentations from clinical key opinion leaders and include personal testimony from an RNS patient about their experience with the system.
NeuroPace (NASDAQ: NPCE) announced its participation in the 2024 American Epilepsy Society Annual Meeting (AES 2024) at the Los Angeles Convention Center from December 6-10, 2024. The company's RNS System will be featured in over 70 scientific presentations and posters.
At booth #2119, NeuroPace will showcase their responsive neuromodulation technology, highlighting 82% seizure reduction at three years and improved quality of life without chronic side effects common in other neuromodulation therapies. The company is hosting demonstrations, panels, and networking events, including a Fellows Networking Reception and a Product Theater presentation on 'New Frontiers in Responsive Neuromodulation.'
NeuroPace announced completion of enrollment and implant procedures in its feasibility IDE study of the RNS System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood-onset epilepsy. The study, funded by a $9.3 million NIH grant, enrolled 20 patients aged 12 and older across six sites to evaluate the safety and effectiveness of brain-responsive stimulation for LGS treatment.
The study includes a one-year open label period followed by an 18-month long-term follow-up. LGS affects patients severely, with 85% continuing to have seizures into adulthood, 98% suffering from intellectual disability, and affected individuals being 12 times more likely to die prematurely than their peers.
NeuroPace reported a 28% year-over-year revenue increase to $21.1 million in Q3 2024, driven by higher RNS System sales. The company raised its full-year 2024 revenue guidance to $78-80 million. Gross margin was strong at 73.2%. Cash burn decreased to $1.8 million, with an increase in cash and short-term investments to $56.8 million. Operating expenses rose to $19.7 million, primarily due to increased R&D and SG&A costs. Net loss narrowed to $5.5 million from $7.3 million in Q3 2023. Management highlighted positive three-year data from a Post-Approval Study and announced an investor day in Q1 2025.
NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. The study, involving over 300 patients from more than 30 Level 4 Comprehensive Epilepsy Centers in the US, is the largest prospective trial in neuromodulation for drug-resistant focal epilepsy. The RNS System is the only neuromodulation device that provides stimulation and monitors patient response over time. The study will continue to a five-year follow-up endpoint as part of the system's initial FDA approval.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, has announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors can access a live and archived webcast of the event at the provided link. Those interested in participating via telephone can dial +1-877-407-3982 and reference Conference ID 13749123. The webcast will be archived on the company's investor relations website for at least 90 days after the event.